1 Min Read
Feb 26 (Reuters) - Destiny Pharma Plc:
* ANNOUNCES THAT US FDA ACCEPTED AN INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR COMPANY’S LEAD CLINICAL DRUG CANDIDATE, XF-73 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.